The angiographic and clinical outcomes after coronary stenting in patients with metabolic syndrome

Xu, Di; Guo, Yan; Wang, Hui; Gu, Bing; Liu, Genyan; Zhou, Chuanwei; Wu, Xin; Wang, Junhong; Cao, Kejiang

doi:10.1016/j.atherosclerosis.2011.12.016

« Previous Next »Atherosclerosis
Volume 221, Issue 2 , Pages 416-421, April 2012

The angiographic and clinical outcomes after coronary stenting in patients with metabolic syndrome

Di Xu
- Department of Gerontology, the first affiliated hospital of Nanjing Medical University, Nanjing, 210029,PR China
- These two authors contributed equal to this work.
Yan Guo
- Department of Gerontology, the first affiliated hospital of Nanjing Medical University, Nanjing, 210029,PR China
Hui Wang
- Department of Gerontology, the first affiliated hospital of Nanjing Medical University, Nanjing, 210029,PR China
- Department of Cardiology, The Shengze Hospital of Jiangsu Province, SuZhou, 215002, PR China
- These two authors contributed equal to this work.
Bing Gu
- Department of Clinical Laboratory Medicine, the first affiliated hospital of Nanjing Medical University, Nanjing, 210029,PR China
Genyan Liu
- Department of Clinical Laboratory Medicine, the first affiliated hospital of Nanjing Medical University, Nanjing, 210029,PR China
Chuanwei Zhou
- Department of Gerontology, the first affiliated hospital of Nanjing Medical University, Nanjing, 210029,PR China
Xin Wu
- Department of Clinical Laboratory Medicine, Benq Medical Center, Nanjing Medical University, Nanjing, 210009, PR China
Junhong Wang
- Department of Gerontology, the first affiliated hospital of Nanjing Medical University, Nanjing, 210029,PR China
- Corresponding author. Tel.: +86 25 83718836 5081; fax: +86 25 83718836 5081.
Kejiang Cao
- Department of Gerontology, the first affiliated hospital of Nanjing Medical University, Nanjing, 210029,PR China

Received 11 October 2011; received in revised form 7 December 2011; accepted 13 December 2011. published online 01 February 2012.

Highlights

► Metabolic syndrome is a risk factor in CAD patients following stent implantation. ► DES implantation decreases angiographic events in metabolic syndrome patients. ► Adequate treatment of MetS is required to improve the outcome in CAD patients.

Abstract

Background

Metabolic syndrome (MetS) is regarded as a risk factor for coronary artery disease (CAD). But the influence of MetS on morbidity and mortality after stent implantation in CAD patients remains unknown.

Methods

This article presents a meta-analysis of available data on the association between the MetS and the risk of angiographic and clinical outcomes following stent implantation.

Results

MetS was associated with a significant increased risk of post-stent all-cause mortality (odd ratio (OR), 2.17, 95% CI, 1.56–3.01), in-lesion restenosis (OR, 1.35, 95% CI, 1.00–1.84) and major adverse cardiac events (MACE) (OR 1.35, 95% CI 1.13–1.61) in CAD patients. Even with drug-eluting stent (DES) implantation, significant increased risk in all-cause mortality (OR, 2.25, 95% CI, 1.61–3.15) and MACE (OR 1.42, 95% CI 1.14–1.76) were remain in patients with MetS. However, the OR of cardiovascular (CV) mortality (1.25, 95% CI 0.71–2.22), MI (1.27, 95% CI 0.87–1.85) and TLR (OR 1.21, 95% CI 0.96–1.53) was not statistically different between the patients with and without metabolic syndrome.

Conclusions

Metabolic syndrome is an important risk factor in patients with CAD following stent implantation. Although DES implantation decreased the incidence of angiographic events, further progress in adequate treatment of MetS is still required to improve the clinical outcome.

Keywords: Metabolic syndrome, Coronary artery disease, Stents